Home/Pipeline/PanGIA Breast

PanGIA Breast

Breast Cancer

Pre-clinicalActive

Key Facts

Indication

Breast Cancer

Phase

Pre-clinical

Status

Active

Company

PanGIA Biotech

About PanGIA Biotech

PanGIA Biotech is pioneering an AI-driven, multi-fluid diagnostic platform centered on a non-invasive 'True Liquid Biopsy' using urine. The company's PanGIA Analysis System (PAS) applies machine learning to colorimetric biomolecular profiles to detect early-stage cancers with the goal of improving accuracy, accessibility, and patient comfort over traditional methods like blood tests or tissue biopsies. While its lead PanGIA Prostate assay is in use globally for diagnostic research, the company is navigating the path toward FDA approval and commercial scale-up to address the significant global need for better early cancer detection.

View full company profile

Therapeutic Areas

Oncology

Other Breast Cancer Drugs

Drug	Company	Phase	Status
Antifibrotic Therapy Program	MeCo Diagnostics	Pre-clinical	Active
inPROBE for HER2	SDS Optic	Clinical Investigation	Completed (March 2023)
ACT‑BC1	Anthrocell	Preclinical	Active
APA-1000 Breast Thermotherapy System	Medifocus	Phase III	Pivotal Trial Approved (IDE/ITA)
Early‑Detection Breast Cancer Screening	Karkinos Healthcare	Market	Active
Unnamed Breast Cancer Program	Click Therapeutics	Pilot/Phase 2	Active
Lerociclib (Lerocliclib)	Chemogenics BioPharma	Phase 3	Completed Phase 3, awaiting FDA approval
AT-017	Asieris Pharmaceuticals	Not Specified	Active
CDK2 inhibitor	Acellera	Pre-clinical	Hit Identification
NP-G2-044	Novita Pharmaceuticals	Phase 2a	Active (subset)
Maveropepimut-S (MVP-S)	BioVaxys	Clinical Evaluation	Active
Cannabics® BRST-33	CNBX Pharmaceuticals	Discovery	In vitro POC